When a patient with multiple myeloma presents for dental treatment, what should you ask the treating oncologist about?

In a patient with multiple myeloma, the most critical information for dental management is the specific chemotherapy regimen because different agents have different oral and systemic complications. Multiple myeloma is commonly treated with bisphosphonates (zoledronic acid, pamidronate) - which significantly increase MRONJ risk with dental procedures; bortezomib - which can cause peripheral neuropathy; immunosuppressive agents - increasing infection risk; and thalidomide/lenalidomide - which increase VTE risk. Knowing the medications allows appropriate dental treatment modifications. The specific subtype of myeloma (option c) is less relevant than knowing the treatment drugs.